Classical Hematology: A Specialty in Decline?

As workforce shortages persist, this ancient art is undergoing a modern renaissance. Two factors influenced Alfred Ian Lee, MD, PhD, to specialize in classical hematology. The first was joining his father, a pathologist, in viewing...

Online Exclusives

Ruxolitinib Approved for Chronic Graft-Versus-Host Disease

The FDA has approved ruxolitinib for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients 12 years and older whose disease...

Crizanlizumab Approved for Sickle Cell Disease in the U.K.

Crizanlizumab will become the first new therapy in 20 years to be made available through the U.K.’s National Health Service (NHS) for the treatment...

News

From the Blood Journals

Modified EASIX Score Predicts CRS and ICANS Before Severe Symptoms in...

A modified version of the EASIX (Endothelial Activation and Stress Index) score, when calculated prior to and soon after chimeric antigen receptor (CAR) T-cell...

Rituximab Biosimilars Versus Originator: Comparing Long-Term Survival Benefit in DLBCL

A study published in Blood Advances found the three-year rate of overall survival (OS) was similar between Dutch patients with diffuse large B-cell lymphoma...

Multimedia

Kathi Mooney: Impact of Remote Monitoring on Patients with Cancer During...

Remote monitoring and treatment of cancer and treatment-related symptoms during the COVID-19 pandemic was associated with significant reductions in symptom burden and improvements in...

Ann LaCasce: PET Adapted Therapy Allows Omission of Radiation Therapy in...

Ann S. LaCasce, MD, shares data from the Alliance for Clinical Trials in Oncology’s CALGB-50801 trial, which evaluated a PET-adapted approach to cHL therapy.

Paolo Ghia: Ibrutinib Plus Venetoclax Produces Deep Responses in Patients with...

Here, Paolo Ghia, MD, PhD, of Vita-Salute San Raffaele University in Milan, Italy, discusses recent findings from the phase II CAPTIVATE study evaluating fixed-duration...

Vincent Wagner and Ellen Marcus: Use of the Khorana Score to...

Vincent Wagner, MD, and Ellen Marcus, BA, discuss the Khorana score's role in assessing risk of venous thromboembolism (VTE) in patients with gynecological cancers.

On Location

On location

Pilot Study Finds Remote Monitoring of Patients Undergoing Chemotherapy Feasible

Using technology to monitor outpatients undergoing cancer treatments at home was feasible and led to...
On location

Could AP-Led Quality and Safety Grand Rounds Improve Patient Outcomes?

Grand rounds provide an opportunity for oncology advanced practitioners (APs) to discuss quality and safety...
On location

Amino Acids Could Reduce Cancer Treatment–Related Diarrhea

Treatment-related diarrhea is a common adverse event (AE) associated with cancer-directed therapies, negatively affecting patients’...
On location

Study Highlights Barriers to Greater AP Understanding of Immuno-oncology

According to results from a survey of U.S. oncology advanced practitioners (APs), APs express growing...
On location

Does Rehabilitation Improve Physical Well-Being and Quality of Life for Cancer Survivors?

Individualized rehabilitative instruction may lead to improvements in quality of life and significant physical benefits...
On location

A New Clinical Ladder for Advanced Practitioners Improves Retention, Engagement

Five years after implementing a “clinical ladder” for advanced practitioners (APs), Moffitt Cancer Center reports...

Latest Headlines

Advertisement

ASH Directions

ASH Directions

Key Dates and Safety Measures for the 2021 ASH Annual Meeting, and more

Key Dates and Safety Measures for the 2021 ASH Annual Meeting The 63rd American Society of Hematology (ASH) Annual Meeting and Exposition will take place...
ASH Directions

ASH Announces New ASH-AMFDP Hematology Scholars, First 10 Sites Join ASH Research Collaborative SCD...

ASH Publishes Adapted Clinical Practice Guidelines for Management of VTE in Latin America The American Society of Hematology (ASH), in partnership with 12 Latin American...

Sign up for our
eNewsletter!

The Society Pages

NCI Grants $1.8M for Cancer Genome Atlas Research, Sarah Cannon Names Navneet Majhail Physician-in-Chief...

Sarah Cannon Appoints Navneet Majhail as Deputy Physician-in-Chief of Blood Cancers Sarah Cannon Research Institute has named Navneet Majhail, MD, deputy physician-in-chief of blood cancers...
The Society Pages

Remembering Alvin Zipursky, Paul Frenette, and more

Remembering Alvin Zipursky (1930 – 2021) Alvin Zipursky, MD, a leader in the field of pediatric hematology, died on August 10.Dr. Zipursky was professor emeritus...
The Society Pages

ASH Remembers Joel S. Bennett, Cancer Researchers Win Damon Runyon Physician-Scientist Training Awards, and...

Remembering Joel S. Bennett (1942 – 2021) Joel S. Bennett, MD, died of pancreatic cancer on June 21, 2021, at the age of 78.Aside from...

Classical Hematology: A Specialty in Decline?

As workforce shortages persist, this ancient art is undergoing a modern renaissance. Two factors influenced Alfred Ian Lee, MD, PhD, to specialize in classical hematology....

The Drug Shortages Dilemma

In hematology/oncology, drug shortages typically affect older, less expensive drugs, but when no alternatives are available, clinicians may struggle to provide the best care. It’s...

The Preservation Conversation

Discussions about possible infertility in young patients with cancer should happen early, and often. Chemotherapy, radiation, and hematopoietic cell transplantation (HCT) are essential treatment options...